South Dakota Dispatch
SEE OTHER BRANDS

Following the news from South Dakota

Attorney General Jackley Announces South Dakota to Receive $1.5 million as Part of $720 million Settlement with Opioid Drug Makers

FOR IMMEDIATE RELEASE: Thursday, July 10, 2025

Contact: Tony Mangan, Communications Director, 605-773-6878 

PIERRE, S.D. – South Dakota Attorney General Marty Jackley announces South Dakota will receive more than $1.5 million as part of a $720 million national settlement with eight opioid drug makers.

“No amount of money will ever be enough to compensate South Dakota families who have suffered because of the involvement of these companies in the opioid drug crisis,” said Attorney General Jackley. “Now is the time to use these funds to help others in the areas of addiction treatment, prevention, and recovery.”

The eight defendants and the total amount they will pay in funds to address the opioid crisis as part of the deal are:  

  • Mylan (now part of Viatris): $284,447,916 paid over nine years 
  • Hikma: $95,818,293 paid over one to four years 
  • Amneal: $71,751,010 paid over 10 years 
  • Apotex: $63,682,369 paid in a single year 
  • Indivior: $38,022,450 paid over four years 
  • Sun: $30,992,087 paid over one to four years 
  • Alvogen: $18,680,162 paid in a single year 
  • Zydus: $14,859,220 paid in a single year 

South Dakota’s payments go into the National Opioid Settlement Fund administered by the South Dakota Department of Social Services. South Dakota’s share of the latest settlement is part of the expected $79 million that the state will receive from settlements with companies that helped fuel the opioid epidemic.  

                                                                       -30-

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service